EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Comprehensive genomic profiling from C‐CAT database unveiled over 80% presence of oncogenic drivers in anaplastic thyroid carcinoma including BRAF, RAS family, NF1, and FGFR1

Yuki Saito, Hidenori Kage, Kenya Kobayashi, Teru Kamogashira, Osamu Fukuoka, Koji Yamamura, Satoshi Yamashita, Masahiko Tanabe, Katsutoshi Oda, Kenji Kondo

Clinical Endocrinology · 2024

DOI: 10.1111/cen.15098 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Clinical Endocrinology, 2024. Verfasst von Yuki Saito und 9 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Otolaryngology, Head and Neck Surgery, The University of Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Thyroid Carcinoma, Anaplastic, Proto-Oncogene Proteins B-raf, Receptor, Fibroblast Growth Factor, Type 1, Thyroid Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Anaplastic thyroid carcinoma (ATC) is considered a very aggressive carcinoma and has been difficult to treat with therapeutic strategies. This study examines the landscape of genomic alteration in ATC, including the BRAF V600E mutation, and its clinical implications. Design, Patients and Mesurement A retrospective observational study was conducted using collected at the Center for Cancer Genomics and Advanced Therapeutics (C‐CAT) in Japan, utilizing comprehensive genomic profiling data from 102 ATC cases. Additionally, AACR‐GENIE data from 267 cases were analysed for validation. Statistical methods, including the conditional Kendall tau statistic and χ 2 tests, were employed for survival analysis and gene mutation comparisons.

Results

Among 102 ATCs, BRAF , RAS , and other driver mutations were found in 83 cases (81.2%). The prevalence of BRAF V600E mutations was as high as 60%. Co‐mutation analysis identified different genomic profiles in the BRAF, RAS , and wild‐type groups. Despite the diverse molecular backgrounds, no significant differences in clinical variables and overall survival were observed. The analysis considering left‐side amputation suggested that RAS mutations had a poorer prognosis. In the BRAF/RAS wild‐type group, FGFR1 and NF1 were identified as driver mutations, with an accumulation of copy number variations and less TERT promoter mutations. This molecular subgrouping was also supported by the AACR‐GENIE data.

Conclusions

Comprehensive genomic analysis of ATC in Japan revealed distinct molecular subgroups, highlighting the importance of BRAF V600E mutations, particularly V600E, as potential therapeutic targets and suggest the relevance of tailor‐made therapeutic strategies based on genomic profiling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid Carcinoma, AnaplasticProto-Oncogene Proteins B-rafReceptor, Fibroblast Growth Factor, Type 1Thyroid NeoplasmsMutationHumansMaleFemaleRetrospective StudiesMiddle AgedAgedNeurofibromin 1Aged, 80 and overAdultJapanGenomicsras Proteins

Stichwörter der Autor:innen

BRAFC‐CATRAScomprehensive genomic profiingthyroid anaplastic carcinoma

Substanzen

Proto-Oncogene Proteins B-rafReceptor, Fibroblast Growth Factor, Type 1BRAF protein, humanFGFR1 protein, humanNeurofibromin 1NF1 protein, humanras Proteins

Autor:innen und Institutionen

  • Departments of Otolaryngology, Head and Neck Surgery, The University of Tokyo, Tokyo, Japan.
  • Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Department of Breast and Endocrine Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Division of Integrative Genomics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Saito, Y., Kage, H., Kobayashi, K., Kamogashira, T., Fukuoka, O., Yamamura, K., Yamashita, S., Tanabe, M., Oda, K., & Kondo, K. (2024). Comprehensive genomic profiling from C‐CAT database unveiled over 80% presence of oncogenic drivers in anaplastic thyroid carcinoma including BRAF, RAS family, NF1, and FGFR1. Clinical Endocrinology. https://doi.org/10.1111/cen.15098

Vancouver

Saito Y, Kage H, Kobayashi K, Kamogashira T, Fukuoka O, Yamamura K, et al. Comprehensive genomic profiling from C‐CAT database unveiled over 80% presence of oncogenic drivers in anaplastic thyroid carcinoma including BRAF, RAS family, NF1, and FGFR1. Clinical Endocrinology. 2024. doi:10.1111/cen.15098

BibTeX
@article{Saito2024,
  author = {Saito, Yuki and Kage, Hidenori and Kobayashi, Kenya and Kamogashira, Teru and Fukuoka, Osamu and Yamamura, Koji and Yamashita, Satoshi and Tanabe, Masahiko and Oda, Katsutoshi and Kondo, Kenji},
  title = {Comprehensive genomic profiling from C‐CAT database unveiled over 80% presence of oncogenic drivers in anaplastic thyroid carcinoma including BRAF, RAS family, NF1, and FGFR1},
  journal = {Clinical Endocrinology},
  year = {2024},
  doi = {10.1111/cen.15098}
}
Kostenlos starten →